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Objective:  The complement system contributes to autoimmune injury, but its involvement in 
promoting development of autoimmune diabetes is unknown.  This study was aimed to ascertain 
the role of complement C3 in autoimmune diabetes.   
 
Research Design and Methods:  Susceptibility to diabetes development after multiple low dose 
streptozotocin treatment in wild-type (WT) and C3 deficient mice was analyzed.  Bone marrow 
chimeras, luminex, and qRT-PCR assays were performed to evaluate the phenotypic and 
immunological impact of C3 in the development of this model of diabetes. 
 
Results:  Coincident with the induced elevations in blood glucose levels, we documented 
alternative pathway complement component gene expression within the islets of the diabetic WT 
animals. When we repeated the experiments with C3 deficient mice we observed complete 
resistance to disease, as assessed by the absence of histological insulitis and the absence of T cell 
reactivity to islet antigens.  Studies of WT chimeras bearing C3 deficient bone marrow cells 
showed that bone marrow cell-derived C3 and not serum C3 is involved in the induction of 
diabetes in this model. 
 
Conclusions:  The data reveal a key role for immune cell derived C3 in the pathogenesis of 
murine multiple low dose streptozotocin induced diabetes and support the concept that immune 
cell mediated diabetes is in part complement-dependent.    
 
 
ype 1 diabetes mellitus is a T 
cell dependent autoimmune 
disease in which islet antigens 
are presented by antigen presenting cells 
(APCs) to autoreactive T cells, breaking self 
tolerance (1,2).  Following attraction to the 
pancreas, the autoreactive CD4 T cells cause 
beta cell injury in part through secreting 
proinflammatory cytokines that directly act on 
the islet cells (3) as well as by activating 
macrophages that amplify injury (4). 
In previous work we showed that 
during cognate T cell/APC interactions 
immune cell-derived complement activates 
locally, yielding C3a and C5a that bind to 
C3a/C5a receptors (C3aR/C5aR) on both 
partners (5).  The resultant G-protein coupled 
receptor (GPCR) signaling further activates 
the APCs (upregulating costimulatory 
molecule expression and innate cytokine 
production) and directly induces survival and 
proliferation of the responding T cells.  These 
concepts apply to in vivo immunity as T cell 
responses to autoantigens (6-8), transplant 
antigens (9-12), and viruses (5,13) are 
diminished in mice in which immune cells are 
deficient in C3 or C3aR/C5aR, while T cell 
immunity is enhanced in mice in which 
immune cells are deficient in the cell surface 
complement regulatory protein decay-
accelerating factor (DAF, CD55) (8,10).  
These results along with a multitude 
of reports documenting that complement 
contributes to autoimmune injury (14-16) 
prompt the question of the possible 
involvement of the complement effectors in 
promoting the development of T cell 
mediated diabetes. This gap in the 
understanding of the function of complement 
in type 1 diabetes is unexpected, given that 
complement effectors, in particular C3a and 
C5a, are potent proinflammatory mediators 
and that inflammation has long been linked in 
the pathogenesis of type 1 diabetes. 
To test the role of complement C3 on 
the development of T cell mediated diabetes, 
T 
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we employed an established model using 
multiple low dose streptozotocin treatment.  
We chose the MLDS model over the NOD 
model because C3 and the diabetes 
susceptibility genes in the NOD strain are 
closely linked on chromosome 17 (17,18), 
thus impairing our ability to produce C3 
deficient NOD animals.  Streptozotocin 
(STZ), a toxin that binds to the GLUT2 
receptor on pancreatic beta cells, has been 
used for decades to induce diabetes in rodent 
models (19).  When administered at a single 
high dose (Hi-STZ, 180 mg/kg), it induces 
necrosis of the beta cells without leukocytic 
infiltrate.  Collapsed islets and elevated serum 
glucose levels are detectable within 2-3 days 
(20).  In contrast, when STZ is administered 
as multiple low-doses (MLDS, 40 mg/kg/day 
for 5 days), it induces distortion of the islet 
architecture in conjunction with mononuclear 
cell infiltration.  While elevated serum 
glucose can be detected as early as day 7, 2-3 
weeks are typically required for sustained 
diabetes (19).  Rather than necrosis, apoptosis 
is the underlying mechanism of islet cell 
death, documented by findings that animals 
deficient in islet-associated caspase-3 are 
resistant to STZ effects (21).  Current 
concepts are that the apoptosis provides an 
environment in which islet autoantigens can 
be processed and presented by infiltrating 
APCs.  Immune cell mediated injury by 
autoreactive T cells that have escaped thymic 
deletion is the dominant pathogenic 
mechanism (22).  Consistent with this 
hypothesis, studies in the early 1980s 
demonstrated that T cell depleted or deficient 
(nude) animals are resistant to MLDS-induced 
diabetes (23-25) and that T cells from animals 
with MLDS-induced disease can transfer 
diabetes to naïve mice (26,27).   
Herein we report that immune cell C3 
is required for MLDS induced diabetes and 
strikingly, that the C3 must derive from 
immune cells rather than from the serum.  Our 
results suggest that further studies are 
warranted in autoimmune diabetes in humans.  
 
RESEARCH DESIGN AND METHODS  
Reagents and Antibodies. Anti-mouse 
CD45.1-PE, CD45.2-PerCP-Cy5.5, anti- 
mouse IFN-γ and biotinylated anti-IFN-γ 
mAb, anti-Annexin V-PE (BD Biosciences; 
San Jose, CA);  anti-mouse C3-FITC (MP 
Biomedicals; Solon, OH); alkaline 
phosphatase-conjugated anti-biotin antibody 
(Vector Laboratories; Burlingame, CA); 
streptavidin-HRP conjugate (Dako; 
Carpinteria, CA); collagenase P (Roche; 
Mannheim, Germany); zymosan A (Sigma 
Aldrich; St. Louis, MO); streptozotocin 
(Alexis Biochemicals; Farmingdale, NY).  
Mice. BALB/cJ (H-2d), C57BL/6 (H-2b), 
B6.SJL-Ptprca Pepcb/BoyJ (CD45.1), B6.C3-/-, 
and RAG-1-/- (B6.129S7-Rag1tm1Mom/J), nude 
(B6.Cg-Foxn1nu/J) male mice were purchased 
from The Jackson Laboratory (Bar Harbor, 
ME). B6.C3-/- mice were backcrossed (>10 
generations) to BALB/c to obtain 
BALB/c.C3-/-.  C3 deficiency was confirmed 
via zymosan A C3 binding assay (11). Male 
mice were used at ages of 6 to 10 weeks of 
age, housed under specific-pathogen-free 
conditions, and treated in strict compliance 
with regulations established by the 
Institutional Animal Care and Use 
Committee. 
Diabetic model, islet isolation and islet 
transplantation. To induce diabetes, male 
mice (6–10 wk of age) were injected i.p. for 5 
consecutive days with streptozotocin (40 
mg/kg) dissolved in cold 0.1 M citrate buffer 
pH 4.5 as previously described (26). Tail-vein 
glucose was measured between 10 AM and 12 
PM and mice were considered diabetic when 
blood glucose levels were >200 mg/dL in two 
consecutive measurements on the OneTouch 
Ultra Blood Glucose Meter (LifeScan Inc; 
Milpitas, CA).  In some experiments mice 
were treated with a single 180 mg/kg body 
weight i.p. injection of STZ. Islet isolation 
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and transplantation were previously described 
(28).  Isolated islets from male B6 mice were 
cultured overnight and incubated with STZ 
(0.5 mg/ml) for 1 hour, washed, and 
transplanted beneath the renal capsule of 
diabetic male B6 recipients (29).  Islets were 
transplanted 10 days after initiating MLDS or 
5 days after Hi-STZ treatment in the recipient 
mice.  Intraperitoneal glucose tolerance 
testing was performed on day 7 after 
transplantation and the area under the curve 
(AUC) was calculated. 
Generation of bone marrow (BM) chimeric 
mice. BM cells were collected from male WT 
or C3-/- mice of B6 background.  Recipient 
male B6 mice had been lethally irradiated 
with 900 rads (2 doses of 450 rads with 3 hr 
resting period) from a cesium source using a 
Mark I Model 137Cs irradiator (JL Shepherd 
& Associates; An Fenrando, CA). Six hours 
after irradiation, recipient irradiated mice 
received 8×106 BM cells via the tail vein. 
Chimerism of >90% donor origin was 
confirmed at week 8 by staining for CD45.1 
vs. CD45.2 and systemic C3 was assayed by 
flow cytometry via zymosan binding followed 
by staining (11). 
Adoptive Cell Transfer. Splenocytes from 
male WT or C3-/- mice of B6 background 
were obtained by gently grinding moistened 
spleen through a 70-µm filter and washed.  
Red blood cells were lysed with ACK Lysis 
Buffer (Invitrogen; Carlsbad, CA).  
Splenocytes were resuspended in sterile PBS 
at a concentration of 3x106 /200µl for 
intraperitoneal transfer into male B6.C3-/- 
mice.  Twenty-four hours after adoptive 
transfer, recipient B6.C3-/- mice were treated 
with MLDS. 
Annexin V Staining. Isolated islets were 
cultured overnight with STZ (0.5mg/ml) at 
37°C in humidified air and 5% CO2.  Islets 
were disrupted into a single-cell suspension 
and Annexin V staining and analysis was 
performed as manufacturer instructed. 
Flow Cytometry. All flow cytometry 
experiments were performed using a BD 
FACSCanto II (BD Biosciences; San Jose, 
CA) and data were analyzed on FlowJo 
software (TreeStar Inc; Ashland, OR). 
Quantitative RT-PCR. Total RNA was 
extracted from the distal portion of the 
pancreas devoid of lymphoid tissue using 
TriZol solution (Life Technologies; Carlsbad, 
CA) and cDNA was generated with oligo(dT) 
primers. PCR was performed on a CFX96 
Real Time System (Bio-Rad; Hercules, CA) 
with the FastStart QuantiTect SYBR Green 
PCR kit (Qiagen; Valencia, CA) as described 
(28). Quantitative RT-PCR data was 
normalized to cyclophylin.  Primer sequences 
are available upon request. 
Histopathology and Insulitis Evaluation. 
Islet grafts were harvested and fixed in OCT 
compound.  Frozen sections were cut into 5 
µm thick sections and islet morphology and 
leukocyte infiltration were assessed by H&E-
staining.  Islets were graded by a blinded 
investigators for severity of insulitis from a 
scale of 0-4: islets devoid of mononuclear 
cells =0; minimum focal islet infiltrate = 1+; 
peri-islet infiltrate of <25% of islet 
circumference = 2+; peri-islet infiltration and 
<50% intra-islet infiltrate = 3+; intra-islet 
infiltration >50% of islet area = 4+.  The 
insulitis score (%) for each group was 
calculated as:  Sum of (1x number of islets 
with 1+, 2x number of islets with 2+, 3x 
number of islets with 3+, 4x number of islets 
with 4+) divided by 4x total number of islets 
scored  (30).  The calculated ratio represents 
the insulitis score  percentage and was 
expressed as the mean±SEM.  Each study 
group included three mice with a minimum of 
10 islets scored.  
Luminex Assay. Splenocytes were harvested 
on experimental day 0, 10, or 19 from MLDS 
treated male B6 and B6.C3-/- mice.  Dilutions 
of spleen cells were plated in HL-1 media 
stimulated in the presence or absence of 
purified islet cells (5x105/well) and cultured 
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at 37°C in 5% CO2 for 24 h.  Supernatants 
from cultures were collected for 
quantification of cytokines by Bio-Plex Pro 
Mouse Cytokine TH1/TH2 assay.  Assays 
were conducted according to manufacturer’s 
instructions and analyzed on a Bio-Plex 200 
System (Bio-Rad; Hercules, CA). 
Statistics. Results are expressed as 
mean±SEM, unless stated otherwise. 
Differences in gene expression were 
calculated using the nonparametric Mann-
Whitney U tests. P<0.05 was considered as 
statistically significant. Statistical analysis 
was performed with the SPSS Version 16.0 
software package (SPSS Inc; Chicago, IL). 
 
RESULTS 
MLDS induces T cell mediated autoimmune 
diabetes. To verify that MLDS is T cell 
dependent in our pathogen free colony 
(contrasting with previous work done in the 
1980s in which experiments were not done in 
a specific pathogen free environment 
(25,31)we injected WT, RAG1-/-, and nude B6 
mice with MLDS.  In all WT mice we 
detected progressively elevated serum glucose 
levels beginning on experimental day 7 and 
all became diabetic by experimental day 17. 
In contrast, we found that none of the RAG1-/- 
and none of the nude mice developed diabetes 
(Fig. 1A).  In control experiments we 
observed that Hi-STZ (which directly 
destroys islet tissue) induced diabetes by 
experimental day 7 comparably in WT and 
RAG1-/- mice (Fig. 1A). On H&E stained 
pancreas tissues obtained on experimental day 
19 we found significant intra- and peri-islet 
mononuclear infiltration in the pancreas of all 
WTs with a mean insulitis score of 50.4±6.5% 
whereas we noted intact islets without any 
mononuclear cell infiltrates in all RAG1-/- 
mice (Fig. 1B). 
To test whether the MLDS protocol 
induced islet-reactive T cell autoimmunity, 
we reasoned that following syngeneic islet 
transplantation, the primed islet-reactive, 
cellular immune response would rapidly 
destroy the transplanted tissue and induce 
recurrent diabetes.  To test this hypothesis, we 
isolated islets from WT B6 mice, pretreated 
them in vitro with STZ to facilitate 
neoantigen expression (29) and then 
transplanted 500 islets under the kidney 
capsules of syngeneic MLDS-induced 
diabetic B6 mice.  We injected identically 
treated islets into Hi-STZ diabetic B6 
recipient mice as controls.  We observed that 
following transplantation, all animals 
rendered diabetic by either MLDS or Hi-STZ 
initially significantly lowered their serum 
glucose values by day 2 after transplantation, 
demonstrating that the transplanted islets were 
functional (Fig. 1C, D).  Subsequently, the 
serum glucose of all of the transplanted 
MLDS-treated animals increased to 
pretransplant values within 1 week 
posttransplant (Fig. 1C).  In contrast, in the 
Hi-STZ treated mice we found that islet 
transplantation markedly reduced and 
stabilized lower serum glucose in all animals 
and fully normalized serum glucose in 6 of 8 
mice (Fig 1D).  On day 7 following 
transplantation, the MLDS recipients had a 
significantly impaired insulin response after 
i.p. glucose load compared to the Hi-STZ 
treated recipients (Fig. 1E).  When we 
examined the pancreas tissue we found 
mononuclear cell infiltration in the 
transplanted islets from the MLDS treated 
mice but not in the Hi-STZ treated animals 
(Fig. 1F). Control experiments with islets that 
were not treated in vitro with STZ prior to 
transplantation into MLDS mice resulted in 
prolonged euglycemia (n=3) (data not 
shown). Together these experiments support 
the concept that MLDS induces autoimmune 
diabetes whereas Hi-STZ induces diabetes 
through an islet-toxic mechanism.   
C3 is required for MLDS-induced diabetes. 
Because we (8,32,33), and others (34-36) 
showed that immune cell produced 
complement exerts control over T cell 
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autoimmunity in other models, we assessed 
the kinetics of complement component gene 
expression in total pancreatic tissue after 
MLDS administration using qRT-PCR. We 
detected gene transcripts for complement 
components C3 and factor B in  pancreatic 
tissue obtained on experimental day 5 of 
MLDS.. We noted that other complement 
components, receptors and regulators, 
including factor D, C3aR1, C5aR1 and decay 
accelerating factor (DAF) were detectable but 
were not increased during the same time 
period (Fig. 2).  We did not detect C3 or 
factor B transcripts from purified islets 
obtained from untreated animals or from mice 
treated with MLDS on day 5 or day 10 (data 
not shown), suggesting that the pancreatic C3 
derived from peri-islet immune cell infiltrates 
rather than from the islet cells. 
To test whether C3 is required to 
induce diabetes following MLDS we 
administered MLDS to C3-/- mice on both 
C57BL/6 (n=12) and BALB/c (n=7) 
background.  In contrast to the WTs 
(C57BL/6 n= 11, BALB/c n=11) in which 
blood sugars exceeded 200 mg/dL at 
experimental day 11 in all mice, none of the 
C3-/- mice on either background developed 
hyperglycemia (Fig. 3A).  While we found 
histological evidence of insulitis on 
experimental day 19 following MLDS in WT 
mice, we did not observe mononuclear 
infiltration within the islets of C3-/- animals 
(Fig. 3B).  The mean insulitis score was 
50.4±6.5% in WT vs. 5.3±2.7% in C3-/- mice 
(p<0.01) (Fig. 3B).  In control experiments to 
test whether islets lacking C3 limits 
susceptibility to the effects of STZ, we co-
cultured WT and C3-/- islets overnight with 
0.5 mg/ml STZ.  When we then tested the 
cultured islets for apoptosis, we found similar 
levels of Annexin V staining in WT islets and 
C3-/- islets, 50.1% vs. 56.3% respectively 
(Fig. S1). In confirmation of equivalent 
susceptibility to STZ, all Hi-STZ treated C3-/- 
mice (n=4) and WT mice (n=7) developed 
diabetes with identical kinetics to the WT 
controls (Fig. 3A).   
Because mononuclear cell 
chemoattractants CCL2 and CCL3 in addition 
to T cell derived IFN-γ and the innate 
cytokine IL-6 are implicated as mediators of 
insulitis, we measured their gene transcripts in 
pancreatic tissue of MLDS treated WT and 
C3-/- mice.  Compared to WT mice, C3 
deficiency was linked with lower expression 
of these genes, with CCL2 and CCL3 
achieving statistical significance.  Notably, 
we found that these differences were 
associated with lowered expression of the 
macrophage marker CD68 within the 
pancreas (Fig. 3C).    
Diminished T cell immunity to islet antigens 
in C3-/- mice. To test the effect of C3 
deficiency on the islet-reactive T cell 
response, we cultured spleen cells from 
MLDS-treated WT and C3-/- mice (and from 
untreated controls) in the presence or absence 
of purified islet cells and measured cytokine 
production in culture supernatants 24 h later 
(Fig. 4).  These analyses revealed islet 
induced production of TNFα (experimental 
day 10) and IFN-γ (experimental day 19) in 
MLDS treated WT mice.  Splenocytes 
obtained from untreated mice did not respond 
to islet stimulation, confirming that the noted 
cytokine production was induced by MLDS.  
In contrast to the results in WT mice, we did 
not detect cytokines in cultures of day 19 
splenocytes obtained from MLDS treated C3-/- 
mice.  Other cytokines including IL-17 and 
IL-10 were barely detectable and not different 
between groups (data not shown).  
MLDS-induced diabetes requires bone-
marrow-cell-derived C3. Because immune 
cell derived complement plays an integral role 
in adaptive T responses (13,37), we 
transplanted C3-/-  (CD45.2) BM into lethally 
irradiated CD45.1 WT B6 mice (C3-/- 
BM→WT) to produce animals that contained 
serum C3 but possessed C3-/- BM cells.  
Conversely, we transplanted WT B6 CD45.1 
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BM into lethally irradiated CD45.2 C3-/- mice 
(WT BM→C3-/-) to produce animals deficient 
in serum C3 but with C3+ BM derived cells.   
WT BM→WT chimeras on the B6 
background were produced as controls.  
Staining peripheral blood for CD45.1/CD45.2 
and analyzing the cells by flow cytometry 
(Fig. 5A) verified that the immune cells were 
> 90% donor BM-derived.  Zymosan C3 
uptake assays (Fig. 5B) validated the presence 
or absence of C3 in the serum of each animal.  
We did not detect C3 in the sera of any WT 
BM→C3-/- chimeras (same as C3-/-  controls) 
but we observed that all sera from C3-/- 
BM→WT and WT BM→WT chimeras was 
C3+ comparable to WT controls (Fig. 5B).  
When we administered MLDS to the chimeric 
animals, we found that only 2 of 8 C3-/- 
BM→WT chimeras developed diabetes, 
whereas all of the WT BM→C3-/- chimeras 
and all of the control WT BM→WT chimeras 
developed sustained hyperglycemia (Fig. 5C).   
In separate “add back” experiments to 
test the requirement for spleen cell derived C3 
in MLDS induced diabetes, we adoptively 
transferred 3x106 WT or control C3-/- spleen 
cells into C3-/- mice and then treated all 
animals with MLDS.  While 2 of 3 C3-/- mice 
that received WT spleen cells became 
diabetic, none of four animals that received 
C3-/- spleen cells developed hyperglycemia 
(Fig. S2 in the online appendix available at 
http://diabetes.diabetesjournals.org).    
 
DISCUSSION 
Taken together, our findings indicate 
that immune cell derived C3 is required for 
the development of diabetes in the MLDS 
model.  We showed that in WT animals, 
MLDS-induced hyperglycemia and islet 
inflammation are associated with complement 
gene upregulation (Fig. 2). We then 
documented that C3 deficient mice, on 2 
different genetic backgrounds, are resistant to 
MLDS induced diabetes (Fig. 3). This 
protective phenotype occurs in the absence of 
islet inflammation (Fig. 3) and in association 
with diminished islet antigen-induced spleen 
cell-derived IFN-γ and TNFα production (Fig. 
4).  Using a bone marrow chimera strategy 
(and confirmed by spleen cell adoptive 
transfers), we showed that BM derived C3 
and not serum C3 is critical for the 
development of autoimmune diabetes in this 
model (Fig. 5).   
Previous mechanistic work performed 
by our group (5) demonstrated that cognate T 
cell/APC interactions result in release and 
activation of alternative pathway complement 
yielding locally produced C3a and C5a.  
These intermediaries bind to their respective 
receptors, C3aR and C5aR expressed directly 
on T cells, and through regulating AKT 
phosphorylation, augment T cell proliferation 
and prevent T cell apoptosis (5,11).  The C3a 
and C5a also bind to their receptors on APCs, 
upregulating cytokine production and 
costimulatory molecule expression, which 
further amplify the T cell response (5).  In the 
absence of C3 or in the absence of 
C3aR/C5aR, T cell proliferation is prevented, 
T cell apoptosis is enhanced, and APC 
produced cytokines and costimulatory 
molecule expression are reduced (5,11), 
together resulting in diminished cellular 
immune responses.  Our new findings that 
islet-reactive T cell immunity and graft 
inflammation are diminished in MLDS treated 
C3-/- mice without diabetes are consistent with 
these mechanisms. In further support of role 
for these C3aR and C5aR signaling as an 
underlying mechanism for our observations, 
we found that only 1/5 mice deficient in both 
the C3aR and C5aR developed diabetes 
within 30 days after initiation of MLDS 
treatment (Fig. S3).   
As others have demonstrated a key 
role for immune cell derived complement as 
an opsonin (38,39), limited antigen processing 
and presentation of autoantigens may 
contribute to the protective phenotype of the 
C3 deficient mice (40).  Macrophage derived 
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C3, a key regulator of macrophage activation 
(41) may also be important in facilitating 
macrophage mediated islet injury (4,15).  
These, among other effects of C3 on 
regulating innate and adaptive immunity, 
require additional study. 
It is notable that NOD mice develop 
spontaneous autoimmune diabetes despite 
being C5 deficient (42), indicating that C5, 
C5a, and the membrane attack complex (43) 
are not required in the pathogenesis of 
diabetes in that model system.  Whether C3 
and/or its activation cleavage products, C3a, 
C3b or C3dg are involved in the pathogenesis 
of diabetes in NOD mice is an issue that 
remains to be tested.  However, the generation 
of C3-/- NOD mice is improbable due to the 
fact that both C3 and the diabetes susceptible 
H-2Kd genes are located on chromosome 17 
(17,18). 
 Our data support the interpretation 
that MLDS induced diabetes is in part an 
autoreactive, T cell mediated process.  We 
showed that both T cell deficient nude mice 
and T and B cell deficient Rag1-/- mice do not 
develop hyperglycemia despite administration 
of MLDS that is pathogenic in WT animals 
(Fig. 1).  Our documentation of recurrent 
hyperglycemia following syngeneic islet 
transplantation of MLDS induced diabetic 
animals, but not diabetic mice induced by Hi-
STZ (Fig. 1) supports this interpretation.  
In summary, this work demonstrates 
an unanticipated key role for immune cell 
derived C3 in the pathogenesis of murine 
autoimmune diabetes.  These results argue 
that studies testing the function of immune 
cell derived complement in human diabetes 
are warranted.   
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Figure Legends 
 
Figure 1. MLDS-induced diabetes is T cell dependent.  
(A) Cumulative diabetes incidence and mean blood glucose levels in MLDS WT (n=11), MLDS 
Rag1-/- (n=7), MLDS nude (n=5), Hi-STZ WT (n=7), and Hi-STZ Rag1-/- (n=4) mice.  (B) 
Histopathology of pancreatic sections from WT and Rag1-/- mice stained with H&E from 
experimental day 19 MLDS mice reveal infiltration present in WT but absent in Rag1-/- mice.  
Arrowhead indicates areas of infiltration; original magnification x200.  500 islets were pretreated 
with 0.5 mg/ml STZ for 1 hour then transplanted into (C) MLDS (n=7) and (D) Hi-STZ (n=8) 
treated syngeneic recipients. Individual blood glucose levels are shown.   (E) Histopathology of 
transplanted islets from MLDS and Hi-STZ treated mice stained with H&E day 15 after 
transplantation.  Heavy infiltration (arrowhead) was present in the transplanted islets from 
MLDS but not Hi-STZ mice; original magnification x200.  (F) AUC was calculated from 
glucose tolerance test performed on day 7 after islet transplantation in addition to control 
nondiabetic mice (n=6). 
 
Figure 2. MLDS induces the differential expression of complement genes.  
Total pancreata were isolated from MLDS treated WT mice on experimental day 0, 5, and 10 and 
complement genes were analyzed by qRT-PCR (n=6 per time point). C3 and factor B mRNA 
expression levels (normalized to cyclophilin) increased significantly after MLDS while factor D, 
C3aR1, and C5aR1 remained unchanged.  DAF expression showed increasing trend.  Box and 
whisker blots show the medians, and the percentile values (10, 25, 75, 90) for normalized 
mRNA. 
 
Figure 3. C3 deficiency protects from MLDS-induced diabetes.  
(A) Cumulative diabetes incidence and average blood glucose levels of WT or C3-/- mice on both 
the B6 and Balb/c background after administration of MLDS (n=7-11 per group) or Hi-STZ 
(n=3-4); **p<0.01 (comparing blood glucose level of WT vs C3-/- on day 17). (B)  
Histopathology of pancreata on experimental day 19 of MLDS showing mononuclear cell 
infiltration in WT but not in C3-/- mice.   Arrowheads indicate areas of infiltration; original 
magnification x200.  Mean insulitis scores (%±SEM) of mice on experimental day 19 were 
obtained from three mice for each group. p<0.01  (C) qRT-PCR of CCL2, CCL3, IFN-γ, IL-6, 
and macrophages (CD68) from total pancreata (normalized to cyclophilin) on experimental day 
0, 5, and 10 after initiation of MLDS (n=6 per group and time point) with C3-/- mice with lower 
expression compared to WT mice.  Box and whisker blots show the medians, and the percentile 
values (10, 25, 75, 90) for normalized mRNA.   
 
Figure 4. Presence of C3 is required in T cell priming and activation. 
Cytokines produced by splenocytes isolated from MLDS treated mice and then stimulated with 
islet cells for 24 hours. C3-/- cells had significantly lower production of TNFα (experimental day 
10) and IFN-γ (experimental day 19) compared to WT. Supernatants were analyzed in duplicates 
by Luminex and the data shown are representative of three independent experiments.  
 
Figure 5. Functional C3 on BM derived cells and not systemic C3 is required for 
development of MLDS-diabetes.  
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(A) C3-/- BM→WT (n=8), WT BM→C3-/-(n=6), and WT BM→WT (n=6) chimeric mice were 
stained for CD45.2 and CD45.1 and analyzed by flow cytometry to verify lethal irradiation and 
bone marrow engraftment on week 8.  (B) Zymosan C3 binding assay confirming presence of 
systemic C3 in WT and absence in C3-/- mice. (C) Cumulative diabetes incidence and average 
blood glucose levels after administration of MLDS in chimeric mice.  Results represent two 
independent experiments. 
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